These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 29932235)

  • 21. The association between steatosis and diabetes with hepatocellular carcinoma in non-genotype 3 chronic hepatitis C patients.
    Yen YH; Lin MT; Kuo FY; Chang KC; Tsai MC; Tseng PL; Wu CK; Lin JT; Hu TH; Lu SN; Wang JH; Hung CH; Chen CH
    Liver Int; 2018 Jun; 38(6):1064-1073. PubMed ID: 29164767
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IL17A gene polymorphism, serum IL17 and total IgE in Egyptian population with chronic HCV and hepatocellular carcinoma.
    ELBassuoni MA; Abd El Fatah G; Zaghla H
    Immunol Lett; 2015 Dec; 168(2):240-5. PubMed ID: 26367076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of soluble MICA levels in the serum of patients with advanced hepatocellular carcinoma.
    Li JJ; Pan K; Gu MF; Chen MS; Zhao JJ; Wang H; Liang XT; Sun JC; Xia JC
    Chin J Cancer; 2013 Mar; 32(3):141-8. PubMed ID: 22704489
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical significance of SNP (rs2596542) in histocompatibility complex class I-related gene A promoter region among hepatitis C virus related hepatocellular carcinoma cases.
    Mohamed AA; Elsaid OM; Amer EA; Elosaily HH; Sleem MI; Gerges SS; Saleh MA; El Shimy A; El Abd YS
    J Adv Res; 2017 Jul; 8(4):343-349. PubMed ID: 28417047
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
    Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
    J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.
    Ng KJ; Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC
    Clin Interv Aging; 2016; 11():1035-41. PubMed ID: 27536084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of major histocompatibility complex class I chain-related gene A microsatellite polymorphism and hepatocellular carcinoma in South China Han population.
    Jiang X; Zou Y; Huo Z; Yu P
    Tissue Antigens; 2011 Aug; 78(2):143-7. PubMed ID: 21644931
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma in Asian chronic hepatitis C patients: A longitudinal study.
    Yen YH; Tsai MC; Wu CK; Chang KC; Hung CH; Chiu KW; Lu SN; Wang JH; Chen CH; Kee KM; Kuo YH; Tseng PL; Lin MT; Huang CM; Lin JT; Hu TH
    J Formos Med Assoc; 2018 Sep; 117(9):833-840. PubMed ID: 29089161
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interaction Between Polymorphisms of IFN-γ and MICA Correlated with Hepatocellular Carcinoma.
    Li H; Liu F; Zhu H; Zhou X; Lu J; Chang H; Hu J
    Med Sci Monit; 2016 Feb; 22():549-53. PubMed ID: 26893439
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The relationship between major histocompatibility complex class I chain-related antigens A (MICA)-129 gene polymorphism, soluble MICA level and ulcerative colitis].
    Zhao J; Jiang Y; Lei Y; Chen LP; Yi FM; Wang CG; Zou KF; Xia B
    Zhonghua Nei Ke Za Zhi; 2011 Apr; 50(4):311-5. PubMed ID: 21600151
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index.
    Lee K; Sinn DH; Gwak GY; Cho HC; Jung SH; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Gut Liver; 2016 Sep; 10(5):796-802. PubMed ID: 27114418
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Post-treatment fibrotic modifications overwhelm pretreatment liver fibrosis in predicting HCC in CHC patients with curative antivirals.
    Huang CF; Yeh ML; Huang CI; Liang PC; Lin YH; Lin ZY; Chen SC; Huang JF; Dai CY; Chuang WL; Yu ML
    Hepatol Int; 2018 Nov; 12(6):544-551. PubMed ID: 30426395
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum PAI-1 and PAI-1 4G/5G Polymorphism in Hepatitis C Virus-Induced Cirrhosis and Hepatitis C Virus-Induced Hepatocellular Carcinoma Patients.
    El Edel RH; Essa ES; Essa AS; Hegazy SA; El Rowedy DI
    Viral Immunol; 2016 Nov; 29(9):510-515. PubMed ID: 27459171
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study.
    Adhoute X; Penaranda G; Raoul JL; Sellier F; Castellani P; Oules V; Perrier H; Lefolgoc G; Pol B; Campanile M; Bayle O; Beaurain P; Monnet O; Bourlière M
    Eur J Gastroenterol Hepatol; 2018 Apr; 30(4):368-375. PubMed ID: 29384796
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Higher risk of hepatocellular carcinoma in chronic hepatitis B vs chronic hepatitis C after achievement of virologic response.
    Kim GA; Han S; Kim HD; An J; Lim YS
    J Viral Hepat; 2017 Nov; 24(11):990-997. PubMed ID: 28499070
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
    Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
    J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The toll-like receptor 2 (TLR2) -196 to -174 del/ins polymorphism affects viral loads and susceptibility to hepatocellular carcinoma in chronic hepatitis C.
    Nischalke HD; Coenen M; Berger C; Aldenhoff K; Müller T; Berg T; Krämer B; Körner C; Odenthal M; Schulze F; Grünhage F; Nattermann J; Sauerbruch T; Spengler U
    Int J Cancer; 2012 Mar; 130(6):1470-5. PubMed ID: 21500195
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between steatohepatitis biomarkers and hepatocellular carcinoma after hepatitis C elimination.
    Ogawa E; Takayama K; Hiramine S; Hayashi T; Toyoda K
    Aliment Pharmacol Ther; 2020 Sep; 52(5):866-876. PubMed ID: 32697871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficacy and safety of pegylated interferon plus ribavirin combination therapy in chronic hepatitis c patients with hepatocellular carcinoma post curative therapies - a multicenter prospective trial.
    Huang JF; Yu ML; Huang CF; Chiu CF; Dai CY; Huang CI; Yeh ML; Yang JF; Hsieh MY; Hou NJ; Lin ZY; Chen SC; Wang LY; Chuang WL
    J Hepatol; 2011 Feb; 54(2):219-26. PubMed ID: 21056500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.